KALA Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -10.55%, SMA50 -28.98%, SMA200 -91.06%). The stock’s 14-day RSI is 37.09 (weak momentum), while the ATR of 0.05 points to moderate volatility. The stock remains hovering near 52-week lows, trading -98.16% below its high and over 7.71% above its low. Average 10-day trading volume of 74.16 thousand shares is below the 3-month average of 171.74 thousand, indicating normal recent market interest.

KALA BIO, Inc. generated EPS of -$5.94 over the past year. Five-year average earnings growth is 40.66%. The latest quarter delivered EPS of -$0.14. The next quarter is forecast at $nan. Next year's EPS is expected at $34.23. Analyst sentiment is bullish. Analyst rating data shows there are 3 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $15.00. The high target offers 1246.15% upside. The low target suggests 476.92% downside. The mean target is $28.25. This offers 986.54% upside. KALA BIO, Inc. earnings surprise history is frequent misses against expectations. The quarter that ended May 15, 2026, missed forecasts by -98.35%. The prior quarter beat by -605.88%. Over the last six quarters, Apple has recorded several small beats. These include -23.68% in March 31, 2025.

KALA BIO, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.93. This means the shares are trading above this model’s fair value.

KALA BIO, Inc. has 7.02 million shares outstanding. The public float is 4.25 million shares, elevated short interest at 6.87% of float. This equals 348.23 thousand shares. The short ratio is 1.71 days. Institutional investors hold 0.75% of the float. Insiders own 0.01%. Shah Rajeev M. holds 7.04 million shares, RA CAPITAL MANAGEMENT, L.P. has 7.04 million shares and RA CAPITAL MANAGEMENT, LLC has 4.54 million shares.

KALA BIO, Inc. (NASDAQ:KALA) closed at $2.47 USD, losing -$0.13 (-5.00%) from the previous close of $2.60. The stock is currently trading near its 52-week low $2.47 and $1.03 thousand. With a market capitalization of about $54.17 million, KALA BIO, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-2.24). Key stats such as the average daily volume over the past year has been around 164.84 thousand shares, volume is running light vs its 52-week average. Headquartered in Arlington, MA, KALA BIO, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Avi Minkowitz, the company employs approximately 38 people and listed since July 20, 2017. Kala Bio, Inc. is a biopharmaceutical company.

Our AI price prediction model suggests that KALA BIO, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -85.77%, with price expected at $0.37 by June 03, 2026, within a range of $0.00 to $2.08 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by August 19, 2026, with a range of $0.00 to $19.68. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by May 21, 2027, within a range of $0.00 to $19.28.

KALA BIO, Inc. (NASDAQ:KALA) shares are flat 8.4% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows KALA BIO, Inc. trading at a premium to the broader market with a P/E of -1.06. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $19.68, suggesting 656.92% upside. Our AI forecast model points to short-term weakness (-85.77% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

KALA BIO, Inc. trades at a P/E ratio of -1.06, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.93 suggesting the stock is closer to book value. The P/FCF stands at -2.15, also below market averages.